5-lipoxygenase-activating protein: Difference between revisions

Jump to navigation Jump to search
m (task, replaced: Stroke; A Journal of Cerebral Circulation → Stroke: A Journal of Cerebral Circulation (2) using AWB)
 
m (1 revision imported)
 
(One intermediate revision by one other user not shown)
Line 4: Line 4:
== Function ==
== Function ==


FLAP is necessary for the activation of [[5-lipoxygenase]] and therefore for the production of [[leukotriene]]s, [[5-hydroxyeicosatetraenoic acid]], [[5-oxo-eicosatetraenoic acid]], and [[specialized pro-resolving mediators]] of the [[lipoxin]] and [[resolvin]] classes.<ref name="Peters-Golden">{{cite journal | vauthors = Peters-Golden M, Brock TG | title = 5-lipoxygenase and FLAP | journal = Prostaglandins, Leukotrienes, and Essential Fatty Acids | volume = 69 | issue = 2-3 | pages = 99–109 | year = 2003 | pmid = 12895592 | doi = 10.1016/S0952-3278(03)00070-X }}</ref><ref name="pmid25359497">{{cite journal | vauthors = Serhan CN, Chiang N, Dalli J, Levy BD | title = Lipid mediators in the resolution of inflammation | journal = Cold Spring Harbor Perspectives in Biology | volume = 7 | issue = 2 | pages = a016311 | year = 2015 | pmid = 25359497 | doi = 10.1101/cshperspect.a016311 | url = }}</ref>  It is an integral protein within the nuclear membrane.  FLAP is necessary in synthesis of leukotriene, which are lipid mediators of inflammation that is involved in respiratory and cardiovascular diseases. FLAP functions as a membrane anchor for 5-lipooxygenase and as an amine acid-bind protein. How FLAP activates 5-lipooxygenase is not completely understood, but there is a physical interaction between the two. FLAP structure consist of 4 transmembrane alpha helices, but they are found in 3’s( trimer) forming a barrel. The barrel is about 60 A high and 36 A wide.<ref name="FergusonMcKeever2007">{{PDB|2q7r}};{{cite journal | vauthors = Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW | title = Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein | journal = Science | volume = 317 | issue = 5837 | pages = 510–2 | date = July 2007 | pmid = 17600184 | doi = 10.1126/science.1144346 }}</ref>
FLAP is necessary for the activation of [[5-lipoxygenase]] and therefore for the production of [[leukotriene]]s, [[5-hydroxyeicosatetraenoic acid]], [[5-oxo-eicosatetraenoic acid]], and [[specialized pro-resolving mediators]] of the [[lipoxin]] and [[resolvin]] classes.<ref name="Peters-Golden">{{cite journal | vauthors = Peters-Golden M, Brock TG | title = 5-lipoxygenase and FLAP | journal = Prostaglandins, Leukotrienes, and Essential Fatty Acids | volume = 69 | issue = 2–3 | pages = 99–109 | year = 2003 | pmid = 12895592 | doi = 10.1016/S0952-3278(03)00070-X }}</ref><ref name="pmid25359497">{{cite journal | vauthors = Serhan CN, Chiang N, Dalli J, Levy BD | title = Lipid mediators in the resolution of inflammation | journal = Cold Spring Harbor Perspectives in Biology | volume = 7 | issue = 2 | pages = a016311 | year = 2015 | pmid = 25359497 | doi = 10.1101/cshperspect.a016311 | pmc=4315926}}</ref>  It is an integral protein within the nuclear membrane.  FLAP is necessary in synthesis of leukotriene, which are lipid mediators of inflammation that is involved in respiratory and cardiovascular diseases. FLAP functions as a membrane anchor for 5-lipooxygenase and as an amine acid-bind protein. How FLAP activates 5-lipooxygenase is not completely understood, but there is a physical interaction between the two. FLAP structure consist of 4 transmembrane alpha helices, but they are found in 3’s( trimer) forming a barrel. The barrel is about 60 A high and 36 A wide.<ref name="FergusonMcKeever2007">{{PDB|2q7r}};{{cite journal | vauthors = Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW | title = Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein | journal = Science | volume = 317 | issue = 5837 | pages = 510–2 | date = July 2007 | pmid = 17600184 | doi = 10.1126/science.1144346 }}</ref>


== Clinical significance ==
== Clinical significance ==
Line 29: Line 29:
* {{cite journal | vauthors = Zintzaras E, Rodopoulou P, Sakellaridis N | title = Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE gene-disease association review and meta-analysis | journal = American Journal of Epidemiology | volume = 169 | issue = 5 | pages = 523–32 | date = March 2009 | pmid = 19126581 | doi = 10.1093/aje/kwn368 }}
* {{cite journal | vauthors = Zintzaras E, Rodopoulou P, Sakellaridis N | title = Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE gene-disease association review and meta-analysis | journal = American Journal of Epidemiology | volume = 169 | issue = 5 | pages = 523–32 | date = March 2009 | pmid = 19126581 | doi = 10.1093/aje/kwn368 }}
* {{cite journal | vauthors = van der Net JB, Janssens AC, Defesche JC, Kastelein JJ, Sijbrands EJ, Steyerberg EW | title = Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia | journal = The American Journal of Cardiology | volume = 103 | issue = 3 | pages = 375–80 | date = February 2009 | pmid = 19166692 | doi = 10.1016/j.amjcard.2008.09.093 }}
* {{cite journal | vauthors = van der Net JB, Janssens AC, Defesche JC, Kastelein JJ, Sijbrands EJ, Steyerberg EW | title = Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia | journal = The American Journal of Cardiology | volume = 103 | issue = 3 | pages = 375–80 | date = February 2009 | pmid = 19166692 | doi = 10.1016/j.amjcard.2008.09.093 }}
* {{cite journal | vauthors = Liu J, Sun K, Bai Y, Zhang W, Wang X, Wang Y, Wang H, Chen J, Song X, Xin Y, Liu Z, Hui R | title = Association of three-gene interaction among MTHFR, ALOX5AP and NOTCH3 with thrombotic stroke: a multicenter case-control study | journal = Human Genetics | volume = 125 | issue = 5-6 | pages = 649–56 | date = June 2009 | pmid = 19373490 | doi = 10.1007/s00439-009-0659-0 }}
* {{cite journal | vauthors = Liu J, Sun K, Bai Y, Zhang W, Wang X, Wang Y, Wang H, Chen J, Song X, Xin Y, Liu Z, Hui R | title = Association of three-gene interaction among MTHFR, ALOX5AP and NOTCH3 with thrombotic stroke: a multicenter case-control study | journal = Human Genetics | volume = 125 | issue = 5–6 | pages = 649–56 | date = June 2009 | pmid = 19373490 | doi = 10.1007/s00439-009-0659-0 }}
* {{cite journal | vauthors = Zhao J, Quyyumi AA, Patel R, Zafari AM, Veledar E, Onufrak S, Shallenberger LH, Jones L, Vaccarino V | title = Sex-specific association of depression and a haplotype in leukotriene A4 hydrolase gene | journal = Psychosomatic Medicine | volume = 71 | issue = 7 | pages = 691–6 | date = September 2009 | pmid = 19622707 | pmc = 3113512 | doi = 10.1097/PSY.0b013e3181b05c57 }}
* {{cite journal | vauthors = Zhao J, Quyyumi AA, Patel R, Zafari AM, Veledar E, Onufrak S, Shallenberger LH, Jones L, Vaccarino V | title = Sex-specific association of depression and a haplotype in leukotriene A4 hydrolase gene | journal = Psychosomatic Medicine | volume = 71 | issue = 7 | pages = 691–6 | date = September 2009 | pmid = 19622707 | pmc = 3113512 | doi = 10.1097/PSY.0b013e3181b05c57 }}
* {{cite journal | vauthors = Matarin M, Brown WM, Dena H, Britton A, De Vrieze FW, Brott TG, Brown RD, Worrall BB, Case LD, Chanock SJ, Metter EJ, Ferruci L, Gamble D, Hardy JA, Rich SS, Singleton A, Meschia JF | title = Candidate gene polymorphisms for ischemic stroke | journal = Stroke: A Journal of Cerebral Circulation | volume = 40 | issue = 11 | pages = 3436–42 | date = November 2009 | pmid = 19729601 | pmc = 2784015 | doi = 10.1161/STROKEAHA.109.558015 }}
* {{cite journal | vauthors = Matarin M, Brown WM, Dena H, Britton A, De Vrieze FW, Brott TG, Brown RD, Worrall BB, Case LD, Chanock SJ, Metter EJ, Ferruci L, Gamble D, Hardy JA, Rich SS, Singleton A, Meschia JF | title = Candidate gene polymorphisms for ischemic stroke | journal = Stroke: A Journal of Cerebral Circulation | volume = 40 | issue = 11 | pages = 3436–42 | date = November 2009 | pmid = 19729601 | pmc = 2784015 | doi = 10.1161/STROKEAHA.109.558015 }}
Line 35: Line 35:
* {{cite journal | vauthors = Strid T, Svartz J, Franck N, Hallin E, Ingelsson B, Söderström M, Hammarström S | title = Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein | journal = Biochemical and Biophysical Research Communications | volume = 381 | issue = 4 | pages = 518–22 | date = April 2009 | pmid = 19233132 | doi = 10.1016/j.bbrc.2009.02.074 }}
* {{cite journal | vauthors = Strid T, Svartz J, Franck N, Hallin E, Ingelsson B, Söderström M, Hammarström S | title = Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein | journal = Biochemical and Biophysical Research Communications | volume = 381 | issue = 4 | pages = 518–22 | date = April 2009 | pmid = 19233132 | doi = 10.1016/j.bbrc.2009.02.074 }}
* {{cite journal | vauthors = Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, Humphries SE, Hingorani AD | title = Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk | journal = Human Molecular Genetics | volume = 18 | issue = 12 | pages = 2305–16 | date = June 2009 | pmid = 19336475 | pmc = 2685759 | doi = 10.1093/hmg/ddp159 }}
* {{cite journal | vauthors = Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, Humphries SE, Hingorani AD | title = Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk | journal = Human Molecular Genetics | volume = 18 | issue = 12 | pages = 2305–16 | date = June 2009 | pmid = 19336475 | pmc = 2685759 | doi = 10.1093/hmg/ddp159 }}
* {{cite journal | vauthors = Vickers PJ | title = 5-Lipoxygenase-activating protein (FLAP) | journal = Journal of Lipid Mediators and Cell Signalling | volume = 12 | issue = 2-3 | pages = 185–94 | date = October 1995 | pmid = 8777565 | doi = 10.1016/0929-7855(95)00018-L }}
* {{cite journal | vauthors = Vickers PJ | title = 5-Lipoxygenase-activating protein (FLAP) | journal = Journal of Lipid Mediators and Cell Signalling | volume = 12 | issue = 2–3 | pages = 185–94 | date = October 1995 | pmid = 8777565 | doi = 10.1016/0929-7855(95)00018-L }}
* {{cite journal | vauthors = Via M, De Giacomo A, Corvol H, Eng C, Seibold MA, Gillett C, Galanter J, Sen S, Tcheurekdjian H, Chapela R, Rodríguez-Santana JR, Rodríguez-Cintrón W, Thyne S, Avila PC, Choudhry S, González Burchard E | title = The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos | journal = Clinical and Experimental Allergy | volume = 40 | issue = 4 | pages = 582–9 | date = April 2010 | pmid = 20067482 | pmc = 2866051 | doi = 10.1111/j.1365-2222.2009.03438.x }}
* {{cite journal | vauthors = Via M, De Giacomo A, Corvol H, Eng C, Seibold MA, Gillett C, Galanter J, Sen S, Tcheurekdjian H, Chapela R, Rodríguez-Santana JR, Rodríguez-Cintrón W, Thyne S, Avila PC, Choudhry S, González Burchard E | title = The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos | journal = Clinical and Experimental Allergy | volume = 40 | issue = 4 | pages = 582–9 | date = April 2010 | pmid = 20067482 | pmc = 2866051 | doi = 10.1111/j.1365-2222.2009.03438.x }}
* {{cite journal | vauthors = Steinhilber D | title = 5-Lipoxygenase: enzyme expression and regulation of activity | journal = Pharmaceutica Acta Helvetiae | volume = 69 | issue = 1 | pages = 3–14 | date = July 1994 | pmid = 7938075 | doi = 10.1016/0031-6865(94)90024-8 }}
* {{cite journal | vauthors = Steinhilber D | title = 5-Lipoxygenase: enzyme expression and regulation of activity | journal = Pharmaceutica Acta Helvetiae | volume = 69 | issue = 1 | pages = 3–14 | date = July 1994 | pmid = 7938075 | doi = 10.1016/0031-6865(94)90024-8 }}

Latest revision as of 11:28, 9 January 2019

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Arachidonate 5-lipoxygenase-activating protein also known as 5-lipoxygenase activating protein, or FLAP, is a protein that in humans is encoded by the ALOX5AP gene.[1][2]

Function

FLAP is necessary for the activation of 5-lipoxygenase and therefore for the production of leukotrienes, 5-hydroxyeicosatetraenoic acid, 5-oxo-eicosatetraenoic acid, and specialized pro-resolving mediators of the lipoxin and resolvin classes.[3][4] It is an integral protein within the nuclear membrane. FLAP is necessary in synthesis of leukotriene, which are lipid mediators of inflammation that is involved in respiratory and cardiovascular diseases. FLAP functions as a membrane anchor for 5-lipooxygenase and as an amine acid-bind protein. How FLAP activates 5-lipooxygenase is not completely understood, but there is a physical interaction between the two. FLAP structure consist of 4 transmembrane alpha helices, but they are found in 3’s( trimer) forming a barrel. The barrel is about 60 A high and 36 A wide.[5]

Clinical significance

Gene polymorphisms in FLAP are suspected of playing a role in Alzheimer's disease.[6] Leukotrienes, which need the FLAP protein to be made, have an established pathological role in allergic and respiratory diseases. Animal and human genetic evidence suggests they may also have an important role in atherosclerosis, myocardial infarction, and stroke. The structure of FLAP provides a tool for the development of novel therapies for respiratory and cardiovascular diseases and for the design of focused experiments to probe the cell biology of FLAP and its role in leukotriene biosynthesis.[5]

Inhibitors

References

  1. Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA (May 1991). "Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP)". The Journal of Biological Chemistry. 266 (13): 8511–6. PMID 1673682.
  2. Yandava CN, Kennedy BP, Pillari A, Duncan AM, Drazen JM (February 1999). "Cytogenetic and radiation hybrid mapping of human arachidonate 5-lipoxygenase-activating protein (ALOX5AP) to chromosome 13q12". Genomics. 56 (1): 131–3. doi:10.1006/geno.1998.5651. PMID 10036194.
  3. Peters-Golden M, Brock TG (2003). "5-lipoxygenase and FLAP". Prostaglandins, Leukotrienes, and Essential Fatty Acids. 69 (2–3): 99–109. doi:10.1016/S0952-3278(03)00070-X. PMID 12895592.
  4. Serhan CN, Chiang N, Dalli J, Levy BD (2015). "Lipid mediators in the resolution of inflammation". Cold Spring Harbor Perspectives in Biology. 7 (2): a016311. doi:10.1101/cshperspect.a016311. PMC 4315926. PMID 25359497.
  5. 5.0 5.1 PDB: 2q7r​;Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW (July 2007). "Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein". Science. 317 (5837): 510–2. doi:10.1126/science.1144346. PMID 17600184.
  6. Manev H, Manev R (2006). "5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease". Medical Hypotheses. 66 (3): 501–3. doi:10.1016/j.mehy.2005.09.031. PMID 16278051.
  7. Musiyenko A, Correa L, Stock N, Hutchinson JH, Lorrain DS, Bain G, Evans JF, Barik S (November 2009). "A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye". Clinical and Vaccine Immunology. 16 (11): 1654–9. doi:10.1128/CVI.00220-09. PMC 2772391. PMID 19759251.

Further reading

External links